Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Aminoquinol. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 known ✓ | Q12809 | 3/20 | 0.54 |
| ▸ | ADRA1D known ✓ | P25100 | 2/20 | 0.50 |
| ▸ | OPRM1 known ✓ | P35372 | 1/20 | 0.50 |
| ▸ | SCN1A known ✓ | P35498 | 1/20 | 0.50 |
| ▸ | SCN2A known ✓ | Q99250 | 1/20 | 0.50 |
| ▸ | SCN3A known ✓ | Q9NY46 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.62 |
| ▸ | MAPT | P10636 | 3/20 | 0.62 |
| ▸ | NSD1 | Q96L73 | 2/20 | 0.62 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.54 |
| ▸ | CHRM2 | P08172 | 3/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.54 |
| ▸ | CHRM5 | P08912 | 3/20 | 0.54 |
| ▸ | ADRA2A | P08913 | 3/20 | 0.54 |
| ▸ | CHRM1 | P11229 | 3/20 | 0.54 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.54 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.54 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aminoquinol SCHEMBL29578527 | 1.00 | HSD17B10 (0.62) | HSD17B10KDM4EMAPTNSD1CXCR4 | |
| Aminoquinol SCHEMBL706642 | 1.00 | HSD17B10 (0.62) | HSD17B10KDM4EMAPTNSD1CXCR4 | |
| Aminoquinol SCHEMBL1612755 | 0.95 | CXCR4 (0.59) | HSD17B10KDM4EMAPTNSD1CXCR4 | |
| Aminoquinol SCHEMBL30002729 | 0.95 | CXCR4 (0.59) | HSD17B10KDM4EMAPTNSD1CXCR4 | |
| Aminoquinol SCHEMBL1612756 | 0.95 | CXCR4 (0.59) | HSD17B10KDM4EMAPTNSD1CXCR4 | |
| Aminoquinol SCHEMBL29462347 | 0.95 | CXCR4 (0.59) | HSD17B10KDM4EMAPTNSD1CXCR4 | |
| SCHEMBL7828401 | 0.90 | CXCR4 (0.51) | HSD17B10KDM4EMAPTNSD1CXCR4 | |
| SCHEMBL12713542 | 0.88 | CHRM2 (0.58) | HSD17B10KDM4EMAPTNSD1CXCR4 | |
| SCHEMBL16142475 | 0.87 | CHRM2 (0.57) | HSD17B10KDM4EMAPTNSD1CXCR4 | |
| SCHEMBL7820026 | 0.87 | CHRM2 (0.57) | HSD17B10KDM4EMAPTNSD1CXCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | CELLECTIS SA (FR) | 2023-12-28 | — | — | US | claimed |
| EP-4251746-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | Cellectis SA (FR) | 2023-10-04 | — | — | EP | claimed |
| US-20230000893-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | UNIV EMORY (US) | 2023-01-05 | — | — | US | claimed |
| WO-2022112596-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | CELLECTIS SA (FR) | 2022-06-02 | — | — | WO | claimed |
| US-20240216414-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | UNIV EMORY (US) | 2024-07-04 | — | — | US | disclosed |
| US-11963972-B2 | Antiviral agents and nucleoside analogs for treatment of Zika virus | EMORY UNIVERSITY (US) | 2024-04-23 | — | — | US | disclosed |
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | CELLECTIS SA (FR) | 2023-12-28 | — | — | US | disclosed |
| EP-4251746-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | Cellectis SA (FR) | 2023-10-04 | — | — | EP | disclosed |
| US-20230000893-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | UNIV EMORY (US) | 2023-01-05 | — | — | US | disclosed |
| WO-2022112596-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | CELLECTIS SA (FR) | 2022-06-02 | — | — | WO | disclosed |
| WO-2017165489-A1 | ANTIVIRAL AGENTS FOR TREATING ZIKA AND DENGUE VIRUS INFECTIONS | EMORY UNIVERSITY (US) | 2017-09-28 | — | — | WO | disclosed |
| US-20130296237-A1 | Use Of Chloroquine To Treat Metabolic Syndrome | UNIV WASHINGTON (US) | 2013-11-07 | — | — | US | disclosed |
| US-20060228425-A1 | Compositions and methods for destabilizing lysosomes to increase oncogenic or aberrant protein degradation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-10-12 | — | — | US | disclosed |
| US-20050124653-A1 | Treatment of dna damage related disorders | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-06-09 | — | — | US | disclosed |
| US-20050032834-A1 | Treatment of DNA damage related disorders | ST. JUDE CHILDREN'S RESEARCH HOSPITAL | 2005-02-10 | — | — | US | disclosed |
| US-20050014785-A1 | Treatment of radiation disorders | PERLEGEN SCIENCES, INC. (US) | 2005-01-20 | — | — | US | disclosed |
| US-20040229908-A1 | Compositions and methods for the treatment of Parkinson's disease and tardive dyskinesias | Greenlee, Winner and Sullivan, P.C. | 2004-11-18 | — | — | US | disclosed |
| WO-2004050837-A2 | TREATMENT OF DNA DAMAGE RELATED DISORDERS | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2004-06-17 | — | — | WO | disclosed |
| US-20020198231-A1 | Compositions and methods for the treatment of Parkinson's disease | Greenlee, Winner and Sullivan, P.C. | 2002-12-26 | — | — | US | disclosed |
| US-6417177-B1 | Chloroquine derivatives for the treatment of Parkinson's disease | ALPHA RESEARCH GROUP, LLC | 2002-07-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014785-A1 | Treatment of radiation disorders | XRCC5, XRCC6, QTRT1 | KCNH2 4378/4885ADRA1D 2475/4885OPRM1 3623/4885 |
| US-20050124653-A1 | Treatment of dna damage related disorders | ERCC1, ERCC5, ERCC2 | KCNH2 4137/4885ADRA1D 4188/4885OPRM1 4532/4885 |
| US-20130296237-A1 | Use Of Chloroquine To Treat Metabolic Syndrome | NPC1L1, ECHS1, PCSK9 | KCNH2 4174/4885ADRA1D 3481/4885OPRM1 3689/4885 |
| US-20050032834-A1 | Treatment of DNA damage related disorders | BRCA1, ERCC4, POLN | KCNH2 4711/4885ADRA1D 4445/4885OPRM1 4834/4885 |
| US-20230000893-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | SAMHD1, PNP, NUDT1 | KCNH2 3605/4885ADRA1D 4057/4885OPRM1 2406/4885 |
| US-20230416786-A1 | USE OF AMINOQUINOLINE COMPOUNDS FOR HIGHER GENE INTEGRATION | ERCC4, LIG4, LIG3 | KCNH2 4314/4885ADRA1D 4574/4885OPRM1 4537/4885 |
| US-11963972-B2 | Antiviral agents and nucleoside analogs for treatment of Zika virus | SAMHD1, PNP, NUDT1 | KCNH2 3605/4885ADRA1D 4057/4885OPRM1 2406/4885 |
| US-20240216414-A1 | Antiviral Agents and Nucleoside Analogs for Treatment of Zika Virus | SAMHD1, PNP, NUDT1 | KCNH2 3605/4885ADRA1D 4057/4885OPRM1 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.